Mesenchymal Precursor Cells for the Continuum of HFrEF From Class II/III Through End-Stage on LVADs

Time: 11:30 am
day: Conference Day 1


  • Intramyocardial MPC Phase 3 trial results showing reduction in CV death, MI and stroke in Class II/III HFrEF Patients
  • Intramyocardial MLC Phase 2/3 trial results showing reduction in CV death and GI bleeding in Class IV ischemic HF patients requiring left ventricular assist device implantation
  • Use of intravenous MLCs to reduce AAV dosage by 100-fold, reduce adverse events and improve efficacy in DMD